Σύγκριση μεθόδων

	UHDRS: Ενοποιημένη Κλίμακα Αξιολόγησης της Νόσου Huntington	AIMS: Κλίμακα Αξιολόγησης Ακούσιων Κινήσεων
Πεδίο	Νευρολογία	Νευρολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	1996	1976
Δημιουργός	Huntington Study Group	National Institute of Mental Health
Τύπος	Clinician-rated and performance-based	Clinician-rated observation
Θεμελιώδης πηγή	Huntington Study Group (1996). Unified Huntington's Disease Rating Scale: Reliability and consistency. Movement Disorders, 11(2), 136-142.	National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press.
Εναλλακτικές ονομασίες	UHDRS, Huntington's Rating Scale	AIMS
Συναφείς	4	3
Σύνοψη	The Unified Huntington's Disease Rating Scale (UHDRS) is the comprehensive, multidomain assessment instrument for Huntington's disease, a neurodegenerative disorder caused by expanded CAG trinucleotide repeats. Developed by the Huntington Study Group in 1996, the UHDRS measures motor, cognitive, functional, and psychiatric manifestations of disease. The UHDRS is the gold-standard outcome measure in Huntington's disease clinical trials and longitudinal natural history studies.	The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure. Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications.